Jingfen Wang

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, National Cancer Center, Linyi People's Hospital, Linzhou Cancer Hospital, International Institute for Strategic Studies

发表论文 91 篇 · 总被引 1020 次 · h-index 15

代表论文

• ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer (2025 · Signal Transduction and Targeted Therapy · 被引 29)
• Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort (2025 · Nature Communications · 被引 15)
• Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. (2025 · Journal of Clinical Oncology · 被引 11)
• Efficacy and safety of KN026 and docetaxel for HER2‐positive breast cancer: a phase II clinical trial (2025 · 癌症：英文版 · 被引 9)
• Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study (2025 · Signal Transduction and Targeted Therapy · 被引 8)
• Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis (2025 · Nature Communications · 被引 5)